仙乐健康(300791) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥582,930,676.96, representing an increase of 8.44% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was ¥54,604,815.53, a decrease of 11.64% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51,992,696.72, down 10.18% from the previous year[5] - The basic earnings per share for Q3 2021 was ¥0.30, down 11.76% year-on-year[5] - Total operating revenue for the current period reached CNY 1,747,962,047.33, an increase from CNY 1,453,340,365.28 in the previous period, representing a growth of approximately 20.3%[33] - Net profit for the current period was CNY 200,383,925.05, compared to CNY 186,047,296.15 in the previous period, reflecting an increase of approximately 7.7%[36] - Basic earnings per share increased to CNY 1.11 from CNY 1.03, while diluted earnings per share rose to CNY 1.12 from CNY 1.03[41] Assets and Liabilities - The total assets as of the end of the reporting period increased by 46.01% year-on-year, reaching ¥3,868,758,514.38[8] - Total liabilities reached CNY 1,349,123,540.94, significantly higher than CNY 466,949,418.29 in the previous period[32] - Total equity attributable to shareholders increased by 15.44% year-on-year, amounting to ¥2,519,634,973.44[8] - The total cash and cash equivalents at the end of the period reached ¥1,037,546,764.09, up from ¥462,270,047.47 in the previous year[49] - Total liabilities amounted to approximately ¥466.95 billion, with non-current liabilities at ¥79.89 billion[59] - The company has a total of ¥387.06 million in current liabilities, indicating a strong liquidity position[58] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥298,028,406.20, an increase of 27.52% compared to the same period last year[5] - The cash inflow from operating activities totaled ¥1,900,708,731.55, an increase of 22.1% compared to ¥1,555,590,103.47 in the previous period[43] - The cash paid to employees was ¥275,832,466.18, an increase of 20.4% compared to ¥228,995,675.13 in the previous period[47] - The cash paid for taxes was ¥86,622,061.12, which is a 96.7% increase from ¥43,999,826.52 in the previous year[47] - The net cash flow from financing activities was ¥948,325,835.89, improving from -¥53,865,531.43 year-over-year[49] Investments and Expenses - The company raised net funds of ¥1,024,892,900 through the issuance of convertible bonds during the reporting period[13] - Research and development expenses for the current period were CNY 59,244,496.97, compared to CNY 49,975,640.01 in the previous period, marking an increase of approximately 18.3%[36] - Cash outflow from investing activities was ¥1,520,658,176.48, a decrease of 41.3% compared to ¥2,588,171,240.27 in the previous period[47] - The net cash flow from investing activities was -¥414,821,096.01, worsening from -¥101,806,586.94 in the previous year[47] Shareholder Information - The company reported a total of 9,104 common shareholders at the end of the reporting period[14] - The company granted 22,440 restricted stocks at a price of CNY 28.82 per share to 13 incentive targets as part of its 2020 restricted stock incentive plan[21] - The first vesting condition of the 2020 restricted stock incentive plan was achieved, allowing 169,620 shares to be vested for 43 eligible incentive targets[21] Corporate Governance - The company successfully completed the election of its third board of directors and supervisory board on July 7, 2021[18] - The audit report for the third quarter was not conducted, indicating a potential area for improvement in financial oversight[61] Growth and Development - The company plans to establish a new subsidiary, "Xianle (Shanghai) Life Technology Co., Ltd.," to enhance its R&D capabilities in Shanghai[21] - The company's cash and cash equivalents amounted to CNY 1,043,260,694.27, significantly up from CNY 216,703,845.28 at the end of 2020, indicating a growth of about 383.5%[22] - The total current assets rose to CNY 2,093,117,608.73, compared to CNY 1,323,832,047.93 at the end of 2020, marking an increase of approximately 58.0%[25]